-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 1, Daiichi Sankyo announced that its oncolytic virus therapy Delytact (teserpaturev/G47Δ) was officially launched in Japan for the treatment of malignant glioma
Delytact is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1).
In August of this year, Delytact was approved for pricing at a price of 1.
However, the approval of Delytact by the Japanese Ministry of Health, Labour and Welfare (MHLW) is conditional, so Daiichi Sankyo must verify the safety and effectiveness of the drug in follow-up trials that produce results within the next seven years
There are currently 4 oncolytic virus products on the market worldwide, namely Rigvir, Encore, Imlygic and Delytact
In addition to several oncolytic virus products that have been on the market, there are also many oncolytic virus products under development worldwide
Among them, Binhui Biologics OH2 injection single drug has entered the phase II clinical trial stage, and the combined use with PD-1/L1 is the first domestic company to be approved to carry out registered clinical trials; Zhongsheng Fu Nuojian Biotechnology VG161 was approved to carry out registered clinical trials in China in September 2020.
